Ventora Medical is thrilled to announce that its project has been awarded $500k funding from the Clinical Translation & Commercialisation Medtech (CTCM) program, an initiative of the Medical Research Future Fund (MRFF), delivered by MTPConnect. This significant funding and support will enable acceleration of the development and commercialisation of our neonatal airway pressure monitoring device, which aims to improve respiratory care for vulnerable infants.
Improving Neonatal Respiratory Care
Respiratory distress is one of the leading causes of morbidity and mortality in newborns, particularly in premature infants with underdeveloped lungs. Current non-invasive breathing support systems are often the first-line treatment for respiratory distress, as they avoid the risks associated with intubation and mechanical ventilation. However, there are several limitations associated with these systems. Their non-invasive nature means that they are susceptible to leaks, leading to uncertain pressure delivery to the infant's airway and high failure rates.
To address this need, Ventora Medical is developing an airway pressure monitor for neonatal patients on non-invasive respiratory support. The device will provide accurate and continuous monitoring of the mean airway pressure without adding invasiveness to treatment and with minimal procedural change. The device aims to provide objective feedback of the delivered pressure to enable clinicians to provide proactive and tailored respiratory treatment. By improving the delivery of non-invasive respiratory support, Ventora’s device aims to reduce failure rates, decrease length of time on respiratory support and improve patient outcomes.
Achieving Critical Milestones
Through the CTCM program, Ventora will receive support from MTPConnect and its partners and funding from the MRFF to achieve critical milestones to accelerate the commercialisation of the device.
Ventora Medical’s Chief Technology Officer, Amy Yu, said: “With this support and funding, Ventora will develop clinical prototypes and conduct a clinical feasibility study to ensure that the device meets the highest standards of effectiveness and safety.
“We are grateful for the recognition and support from MTPConnect through the CTCM program,” said Ms Yu.
Advancing Our Mission
At Ventora Medical, we are committed to empowering clinicians through innovation and helping premature babies breathe through the development and commercialisation of our first product, the Ventora Airway Pressure Monitor. With the support of MTPConnect through the CTCM program, we are excited to continue our journey towards delivering an innovative solution that impacts the lives of vulnerable infants and their families.
Stay tuned for more updates!
See MTPConnect's announcement here.
This project received funding from the Clinical Translation and Commercialisation Medtech program, an initiative of the Australian government’s Medical Research Future Fund, delivered by MTPConnect.
About the Clinical Translation and Commercialisation Medtech (CTCM) Program
The Clinical Translation and Commercialisation Medtech (CTCM) program, delivered by MTPConnect, is a $19.75 million MRFF initiative. The CTCM program identifies and nurtures high quality medical device projects that have commercial potential and supports their translation through early clinical trials.